Company intelligence / Profile preview

Tivorsan Pharmaceuticals

Ownership: Private
Development stage: Other

Overview

Tivorsan Pharmaceuticals developed TVN‑102, a recombinant human biglycan protein for treating Duchenne muscular dystrophy. The company received FDA orphan drug designation for this program and completed preclinical studies showing improved muscle health in animal models. As of the last updates, they were preparing for Phase 1 trials but there are no public records indicating progression beyond preclinical or early IND-enabling work.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Recombinant proteinProteinBiologic
Industry: Biotech

Drug pipeline

2 assets

biglycan

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Parent Project Muscular Dystrophy (PPMD) [grant funding partner]Muscular Dystrophy Association (MDA) [grant funding partner/investor via MDA Venture Philanthropy funder group]

Beyond the preview

Go deeper on Tivorsan Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tivorsan Pharmaceuticals.

Explore the full profile